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Abstract 
Background: Bladder cancer (BC) is the 10th most common cancer in the UK, with about 10,000 new cases annu‑
ally. About 75–85% of BC are non‑muscle invasive (NMIBC), which is associated with high recurrence and progression 
rates (50–60% within 7–10 years). There are no routine biomarkers currently available for identifying BC patients at 
increased risk of developing recurrence. The focus of this research study was to evaluate antibody expression in BC 
patients and their association with cancer recurrence.
Methods: 35 patients scheduled for TURBT were recruited after written informed consent. Ethical approval for the 
project was granted via IRAS (REC4: 14/WA/0033). Following surgical procedure, tissues were preserved in 10% buff‑
ered formalin and processed within 24 h in FFPE blocks. 7 sections (4 µm each) were cut from each block and stained 
for CD31, Human epidermal growth factor receptor‑2 (HER‑2), S100P, Cyclooxygenase‑2 (COX‑2), VEGFR‑3 thrombo‑
modulin and CEACAM‑1 using immunohistochemistry. Clinical outcome measures (obtained via cystoscopy) were 
monitored for up to 6 months following surgical procedure.
Results: There was significantly increased expression of CD31 (p < 0.001), HER‑2 (p = 0.032), S100P (p < 0.001), COX‑2 
(p < 0.001), VEGFR‑3 (p < 0.001) and decreased expression of thrombomodulin (p = 0.010) and CEACAM‑1 (p < 0.001) in 
bladder tumours compared to normal bladder tissues. HER‑2 expression was also significantly associated with cancer 
grade (p = 0.003), especially between grade 1 and grade 2 (p = 0.002) and between grade 1 and grade 3 (p = 0.004). 
There was also a significant association between cancer stage and HER‑2 expression (p < 0.001). Although recurrence 
was significantly associated with cancer grade, there was no association with antibody expression.
Conclusion: Findings from the present study may indicate an alternative approach in the monitoring and manage‑
ment of patients with BC. It is proposed that by allowing urological surgeons access to laboratory markers such as 
HER‑2, Thrombomodulin and CD31 (biomarker profile), potentially, in the future, these biomarkers may be used in 
addition to, or in combination with, currently used scoring systems to predict cancer recurrence. However, verification 
and validation of these biomarkers are needed using larger cohorts.
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Background
Globally, there were approximately 549,393 new blad-
der cancer (BC) diagnoses in 2018 of which about 90% 
are Transitional cell carcinomas (TCC) [1]. An estimated 
80% of TCC are Non-Muscle Invasive (NMIBC) while 
about 20% are Muscle Invasive BC (MIBC). High recur-
rence rates in NMIBC means patients are exposed to fre-
quent hospital visits with increased risks of infection and 
post-operative complications. The Transurethral Resec-
tion of the Bladder Tumour (TURBT) is still the main 
procedure for treatment and diagnosis of BC. Insufficient 
resection has been associated with an increased risk of 
early recurrence [2].
Although there is intense ongoing BC-related research, 
no routinely used biomarkers exist for predicting recur-
rence following TURBT. Cyclooxygenase-2 (COX-2) 
plays important roles in the inflammatory response [3] 
with high expression of COX-2 being reported in high 
grade and high stage colorectal cancer [4] and endome-
trial carcinoma [5].
Thrombomodulin is a 74  kDa membrane receptor 
expressed on endothelial cells with important roles in 
physiological coagulation, inflammation and cancer pro-
motion [6, 7]. The effects of Thrombomodulin activity in 
cancer have been linked to its roles in anticoagulation, 
anti-inflammation and tissue adhesion and proliferation 
[8].
The S100 proteins are associated with cellular processes 
such as regulation of cell cycle, growth, transcription 
and differentiation [9]. It is thought that, when secreted, 
S100P may have paracrine or autocrine signalling effects 
[10], while cellular expression of S100P may interact with 
growth factors and receptors leading to several effects 
such as proliferation [9]. The association between S100P 
and cellular processes such as cell survival, proliferation, 
tumour invasion and angiogenesis have been studied by 
various researchers [9, 11–13].
As an oncogene, HER2 over-amplification causes 
tumourigenesis due to activation of signalling pathways 
such as MAPK [14, 15]. HER2 gene amplification and 
higher protein expression occurs in about 25% of people 
with metastatic breast cancer [16].
Even though VEGFR-3 expression is usually located on 
endothelial cells within the lymphatic system [17] and has 
been mainly involved in lymphangiogensis [18]. Some 
studies have observed that any inhibition of VEGFR-3 
activity, reduces Angiogenic sprouting and vascular net-
work formation [19]. Due to the high recurrence rates in 
BC, measurement of VEGF and their receptors may pro-
vide useful for predicting recurrence and progression.
Decreased expression, down regulation or loss of 
CEACAM-1 expression in tumour cells has previously 
been reported [20, 21]. In hepatocellular carcinoma, loss 
of CEACAM-1 expression is significantly associated with 
high grade and poor survival [22].
CD31 plays various roles in angiogenesis, leucocyte 
migration and activation of integrins [23, 24] and may be 
secreted, membrane bound or localised intracellularly. 
Increased CD31 expression has also been associated with 
worst cancer specific survival [25] and poor prognosis 
[26].
Findings from the present study may indicate an alter-
native approach in the monitoring and management of 
patients with BC. It is proposed that by allowing urologi-
cal surgeons access to laboratory markers such as HER-2, 
Thrombomodulin and CD31 (biomarker profile), poten-
tially, in the future, these biomarkers may be used in 
addition to, or in combination with, currently used scor-
ing systems to predict cancer recurrence. However, veri-
fication and validation of these biomarkers are needed 
using larger cohorts.
Methods
Ethical approval and subject recruitment
Permission for this research study was granted by the 
Research Ethics Service (REC reference 14/WA/0033). 
Subjects recruited for this research attended the Betsi 
Cadwaladr University Health Board (BCUHB) Wrexham 
Maelor Hospital, North Wales for elective procedures for 
the treatment/management of BC (Table  1). 35 patients 
(average age = 74, males = 29 and females = 6) prospec-
tive patients scheduled for a Transurethral Resection of 
the Bladder tumour (TURBT) for the treatment of BC, 
Table 1 Demographic and  clinical characteristics 
of recruited subjects
Age (years)
 Mean 74
 Median 75
 Range 43–95
Sex
 Male 29
 Female 6
Cancer stage
 pTa 22
 pT1 6
 pT2 5
Cancer grade
 Grade 1 9
 Grade 2 11
 Grade 3 13
Cancer recurrence
 Recurrence 14
 No recurrence 21
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were recruited into this research study after informed 
consent.
Tissue preservation, processing and microtomy
Formalin Fixed, Paraffin Embedded (FFPE) tissue blocks 
of recruited patients were retrieved from storage at the 
histopathology department of Ysbyty Glan Clwyd, North 
Wales (UK). At least 12 sections (4  µm each) were cut 
from each patient tissue block using a microtome, placed 
on positively charged glass microscope slides and incu-
bated at  600 C for at least 30 min before proceeding with 
IHC. This process enhances adherence of the tissue to the 
glass slides and ensures stability of the tissue.
Antibodies
Monoclonal anti-CEACAM-1/CD66a (clone: 283324; 
R&D systems UK), monoclonal anti-CD31 (clone: JC70; 
cell marque UK), Polyclonal anti-COX-2 (Clone: SP21; 
cell marque UK), monoclonal anti-HER-2/neu (Clone: 
4B5; Roche diagnostics UK), monoclonal anti-S100P 
(clone: 16/f5; Cell marque UK), monoclonal anti-throm-
bomodulin (clone: 1009; Cell marque UK) and monoclo-
nal anti-VEGFR-3 (clone: AF349; R&D systems UK) were 
used in this study. Antibodies were stored and treated 
according to manufacturer’s instructions.
Immunohistochemistry
Tissue slides were dewaxed using 1X EZ prep solution 
(Ventana Medical Systems, UK), heat and vortex mixing 
and antigen retrieval was carried out using cell condition 
1. VENTANA Antibody Diluent with Casein was used 
to block endogenous proteins. This was followed by the 
application of primary antibodies which primarily were 
mouse and rabbit IgG. The antigens were then visualised 
using Ventana Ultraview DAB universal detection kit. 
The slides were then counter stained using Ventana haer-
matoxylin 1. The slides were washed in warm soapy water 
to remove residual liquid coverslip (oil) and the then 
dehydrated in a series of alcohol and DPX mounted on 
Dako HE autostainer. For each IHC stain, both positive 
and negative control tissue were used to ensure validity 
of the results.
Assessing recurrence
In all patients recruited into this research study, follow 
up data immediately available from follow up clinics was 
retrieved. This information was obtained from outpatient 
clinic as well as BCUHB clinical portal.
Investigating the long-term overall survival rates, 
5-year and 10-year recurrence and progression data are, 
however, beyond the scope of this research. However, 
the short-term information available (up to 2 years post 
TURBT) will be discussed in relation to the biomarkers 
measured and may ultimately provide sufficient and 
accurate clinical data that may help predict or forecast 
NMIBC recurrence and progression.
Statistical analysis
Statistical analysis was undertaken using SPSS (version 
26). With regards to tissue analysis, a chi-square test was 
performed to determine the difference between antibody 
staining in bladder tumour cells in comparison with nor-
mal urothelium. A Kruskal Wallis test was used to deter-
mine the association between clinopathological features 
(such as cancer grade and stage) and expression. In cases 
where there was a significant difference, further post-hoc 
testing was performed using the Mann–Whitney test.
Results
CD31 tissue expression in BC patients
Anti-CD31 primary monoclonal antibody demon-
strated cytoplasmic and membranous staining patterns 
in endothelial cells (Fig. 1). Vascular endothelial cells in 
BC tissues had significantly higher anti CD31 expression, 
compared to normal underlying tissues  (X2(3) = 20.353, 
p < 0.001), as determined by the Chi-square test. With 
respect to cancer grading and staging, there was no sig-
nificant association between patients’ cancer grade and 
CD31  (X2(2) = 2.719, p = 0.257), as determined by the 
Kruskal–Wallis test. However, there was a significant 
association with cancer stage  (X2(2) = 12.276, p = 0.002), 
as determined by the Kruskal–Wallis test.
Thrombomodulin tissue expression in BC patients
The anti-thrombomodulin primary monoclonal antibody 
used in this study shows membranous staining patterns in 
BC tissue sections (Fig. 2). Positive membranous staining 
was reported based on colour intensity and percentage 
of cells that were expressed. Generally, there was a sig-
nificantly reduced thrombomodulin in Bladder tumours, 
compared to normal underlying tissues  (X2(3) = 11.29, 
p < 0.010), as determined by the Chi-square test.
With respect cancer grading and staging, there was no 
significant association between patients’ cancer grade 
and Thrombomodulin  (X2(2) = 0.380, p = 0.83), as deter-
mined by the Kruskal–Wallis test. There was however 
a significant association between patient’s cancer stage 
and Thrombomodulin  (X2(2) = 6.50, p = 0.039), as deter-
mined by the Kruskal–Wallis test.
HER‑2/neu tissue expression in BC patients
The anti-HER-2/neu primary monoclonal antibody used 
in this study shows membranous staining patterns in BC 
tissue sections (Fig.  3). Positive membranous staining 
was reported based on colour intensity and percentage of 
cells staining positive. Generally, there was a significantly 
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higher HER-2/neu expression in Bladder tumours, 
compared to normal underlying tissues  (X2(3) = 8.82, 
p < 0.032), as determined by the Chi-square test.
With respect cancer grading, there was a significant 
association between patients’ cancer grade and HER-2/
neu  (X2(2) = 11.407, p = 0.003), as determined by the 
Kruskal–Wallis test. Further post-hoc testing using 
the Mann–Whitney test revealed significant differ-
ence between grade 1 and grade 2 (Z = -3.042, p = 0.002, 
r = 0.673) and a significant difference between grade 1 
Fig. 1 Anti‑CD31 antibody staining in BC tissues. a Negative: No staining or positive cytoplasmic/membranous staining in < 5% of VE cells in BC 
tissues. b Positive (+: Weak intensity cytoplasmic/membranous staining in up to 20% of VE cells in BC tissues. c Positive (++): Moderate intensity 
cytoplasmic/membranous staining in 20–50% of VE cells in BC tissues. d Positive (+++): Strong cytoplasmic/membranous staining in > 50% of VE 
cells in BC tissues. DAB detection. ×40 magnification. VE,  vascular endothelial
Fig. 2 Anti‑thrombomodulin IHC staining in BC tissues. a Negative: No membranous staining in < 5% of Bladder tumours b Positive (+): Positive 
membranous staining in up to 20% of Bladder tumours. Note the weak positive membranous staining (red arrows). c Positive (++): Positive 
membranous staining in up to 20–50% of Bladder tumours. Note the Moderate colour intensity. d Positive (+++): Positive membranous staining 
in > 50% of Bladder tumours. Note the high colour intensity. DAB detection. ×40 magnification
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and grade 3 (Z = -2.843, p = 0.004, r = 0.606), both with 
a high  Eta2 effect size. There was also a significant asso-
ciation between patient’s cancer stage and HER-2/neu 
 (X2(2) = 16.092, p < 0.001), as determined by the Kruskal–
Wallis test.
S100P tissue expression in BC patients
The anti-S100p primary monoclonal antibody used in this 
study shows cytoplasmic and nuclear staining patterns 
in BC tissue sections (Fig. 4). Generally, there was a sig-
nificant increase in S100P expression in Bladder tumours 
Fig. 3 Anti‑HER‑2/neu antibody staining in BC tissues. a Negative: No staining or weak membranous staining in < 5% of BC tissues. b Positive (+): 
Weak intensity membranous staining in up to 20% BC tumours. c Positive (++): Moderate intensity membranous staining in 20–50% of BC tissues. 
d Positive (+++): Strong intensity membranous staining in > 50% of BC tissues (Brown colour, red arrows). DAB detection. ×40 magnification
Fig. 4 Anti‑S100P antibody staining in BC tissues. a Negative: No staining or positive cytoplasmic/nuclear staining in < 5% of Bladder tumours. b 
Positive (+): Weak Nuclear/cytoplasmic staining in up to 20% of Bladder tumours (black arrows). c Positive (++): Moderate/strong positive nuclear 
and cytoplasmic staining 20–50% of Bladder tumours. d Positive (+++): Strong positive nuclear and cytoplasmic staining in > 50% of Bladder 
tumours. DAB detection. X40 magnification
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compared to those in normal tissues (X2(3) = 41.686, 
p < 0.001), as determined by the Chi-square test.
With respect to cancer grading, there was no sig-
nificant association between patients’ cancer grade and 
anti-S100P expression  (X2(2) = 0.206, p = 0.902), as deter-
mined by the Kruskal–Wallis. There was also no sig-
nificant association between patient’s cancer stage and 
S100P  (X2(2) = 2.134, p = 0.344), as determined by the 
Kruskal–Wallis test.
COX‑2 tissue expression in BC patients
The anti-COX-2 primary monoclonal antibody used in 
this study shows cytoplasmic and membranous stain-
ing patterns in BC tissue sections (Fig.  5). Generally, 
there was a significant increase in COX-2 expression in 
Bladder tumours, compared to those in normal tissues 
(X2(3) = 19.97, p < 0.001), as determined by the Chi-
square test. With respect to cancer grading, there was 
no significant association between patients’ cancer grade 
and anti-COX-2  (X2(2) = 0.96, p = 0.61), as determined 
by the Kruskal–Wallis test. There was also no significant 
association between patient’s cancer stage and S100P 
 (X2(2) = 1.65, p = 0.45), as determined by the Kruskal–
Wallis test.
Anti‑CEACAM‑1 tissue expression in BC patients
The anti-CEACAM-1 primary monoclonal antibody used 
in this study shows cytoplasmic/membranous staining 
patterns in BC tissue sections (Fig.  6). Generally, there 
was a significant change (loss of tissue expression) in 
CEACAM-1 in Bladder tumour, compared to normal tis-
sues (X2(3) = 11.29, p < 0.001), as determined by the Chi-
square test.
There was a significant association between patients’ 
cancer grade and CEACAM-1 expression  (X2(2) = 6.19, 
p = 0.045), as determined by the Kruskal–Wallis. Fur-
ther post-hoc testing using the Mann–Whitney test 
revealed significant difference between grade 1 and grade 
3 (Z = -2.444, p = 0.015, r = 0.509). With respect to can-
cer staging, there was a significant association between 
patient’s cancer stage and CEACAM-1 expression 
 (X2(2) = 10.78, p = 0.005), as determined by the Kruskal–
Wallis test.
Anti‑VEGFR‑3 tissue expression in BC patients
The anti-VEGFR-3 primary monoclonal antibody used 
in this study shows nuclear and cytoplasmic staining pat-
terns in BC tissue sections (Fig. 7). Generally, there was 
a significant increase in VEGFR-3 expression in Bladder 
tumours, compared to normal tissues (X2(3) = 41.71, 
p < 0.001), as determined by the Chi-square test.
With respect to cancer grading, there was a significant 
association between patients’ cancer grade and VEGFR-3 
 (X2(2) = 4.18, p = 0.12), as determined by the Kruskal–
Wallis. There was also no significant association between 
patient’s cancer stage and VEGFR-3  (X2(2) = 2.94, 
Fig. 5 Anti‑COX‑2 antibody staining in BC tissues. a Negative: No staining/Positive cytoplasmic/membranous staining in < 5% of Bladder tumours. b 
Positive (+): Weak positive cytoplasmic/membranous staining in up to 20% of Bladder tumour cells (Brown colour). c Positive (++): Moderate/high 
positive cytoplasmic/membranous staining (brown colour) in in up to 20–50% of Bladder tumours. d Positive (+++): Strong positive cytoplasmic/
membranous staining in in up to > 50% of Bladder tumours (bigger arrow). Note the absence of staining in underlying tissue (smaller arrow). DAB. 
×40 magnification
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p = 0.23), as determined by the Kruskal–Wallis test. 
Table  2 summarises the results for antibody staining in 
bladder cancer patients.
Discussion
The main aim of this study was to evaluate the expres-
sion of various tissue-based biomarkers in BC patients 
and their association with cancer recurrence. This was 
done by assessing IHC staining in patient tissues follow-
ing TURBT for the treatment of BC.
The results from this study showed a significant 
increase in anti-CD31 in vascular endothelial cells 
located in bladder tumour cells with some staining also 
located close to the tumour cells. As a marker of angio-
genesis, these findings potentially show the presence of 
increased angiogenesis within the Bladder tumours. The 
scoring system used in this research examines both stain-
ing intensity and percentage positivity in tumour cells 
and has been used by others [27].
Anti-CD31 patterns reported in this study comple-
ments results by others [28] although those author’s 
used a different patient cohort. Both studies however 
show that, CD31 is a good marker for measuring angi-
ogenesis using IHC. Results from this present study 
disagree with others [29] as no association between 
CD31 and cancer grade was observed. This could be 
Fig. 6 Anti‑CEACAM‑1 staining in BC tissues. a Negative: No staining/Positive membranous staining in < 5% of Bladder tumours. Small blue arrow 
shows weakly expressed bladder tumours. Big blue arrow shows underlying connective tissue. b Positive (+): Moderate membranous staining in up 
to 20% of Bladder tumours. c Positive (++): Positive membranous staining in 20–50% of Bladder tumour cells (Blue arrows). Ventana ultraview DAB 
detection. ×40 magnification
Fig. 7 Anti‑VEGFR3 staining in BC tissues. a Negative: No Staining or < 5% nuclear/cytoplasmic Staining. b Positive (+): Moderate intensity Nuclear/
cytoplasmic staining in up to 25% of Bladder tumours c Positive (++) Moderate intensity nuclear/cytoplasmic staining in 25–50% of Bladder 
tumours (Green arrows). Nonspecific staining in underlying stroma cells (red arrows). d Positive (+++): Strong intensity nuclear/cytoplasmic 
staining in > 50% of Bladder tumour (big blue arrows). Smaller arrow shows nonspecific staining in stroma cells. Ventana Ultraview DAB. ×40 
magnification
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due to differences in cancer types and grading systems. 
Patients with cancer stage pTa presented with higher 
CD31 compared to other BC stages. These findings sug-
gest that increased CD31 in low pTa tumours may have 
an association with angiogenesis.
In this study, loss of expression or reduced throm-
bomodulin was observed within bladder tumour cells 
compared to normal bladder cells. Due to its tumour 
suppressive properties [30], loss of thrombomodulin 
observed in this present study, could potentially cause 
increased tissue differentiation, metastasis and recur-
rence. Although the exact mechanisms are not fully 
understood, earlier studies show that, thrombomodu-
lin maintains cell–cell interactions and also inhibits 
degradation of the ECM; important factors in cancer 
proliferation [31, 32]. Our findings therefore further 
complement these earlier studies by highlighting the 
loss of Thrombomodulin within BC cells. In terms of 
Bladder specific research however, our research pro-
vides new information on Thrombomodulin staining 
patterns in bladder tumours.
High stage BC was significantly associated with 
reduced thrombomodulin suggesting that there was 
reduced cell to cell interaction due to the absence of 
thrombomodulin. This observation is in agreement 
with an earlier study which reported that, decreased 
thrombomodulin was significantly correlated with high 
cancer stage, differentiation and 5 year survival [33]. In 
this current study, there was no association between 
thrombomodulin (at diagnosis) and cancer recurrence. 
This observation should however be further inves-
tigated using larger sample sizes and increasing the 
length of follow up.
Our results also showed reduced CEACAM-1 in 
Bladder tumour cells compared to other tissues. Due 
to its angiogenic properties, an increase in CECAM-1, 
was expected in BC patients before TURBT. Although 
increased tissue expression of CEACAM-1 has been 
reported in human cancers [34], our findings of 
decreased expression may further explain earlier reports 
of a dual role of CEACAM-1 in BC [35]. Furthermore, 
the two IHC reporting systems (traditional scoring sys-
tem using stain intensity/percentage vrs MVD) produced 
different results and raises further issues with validation.
Some studies have associated CEACAM-1 with aggres-
sive tumour behaviour (i.e. high grade, advanced stage, 
metastasis and survival) in different human cancers [36, 
37]. In our study, we report a significant association 
between loss of CEACAM-1 and BC stage and grade. 
Our study further attempts to evaluate this association 
with cancer recurrence. In this regard, there was no asso-
ciation between patients’ CEACAM-1 (at diagnosis) and 
BC recurrence.
There was generally a significant increase in COX-2 
in Bladder tumour cells, compared to those in normal 
tissues. These findings are in agreement with a recent 
study by others in colonic adenocarcinoma tissues [4]. 
The results suggest that tumour cells of epithelial origin 
express high levels of COX-2 probably due to chronic 
inflammation and may potentially be a good biomarker. 
Furthermore, high stage and high grade patients pre-
sented with high staining intensity and percentage of 
tumour cells [4]. These observations were also present 
in the current study and suggests that COX-2 in cancer 
tissues (especially staining intensity) should be further 
investigated in BC.
Table 2 Summarised statistical results for antibody staining in BC
Antibody Overall staining pattern 
in patients’ Bladder tumours 
(Chi square)
Association 
between antibody 
expression and cancer grade 
(Kruskal–Wallis test)
Association 
between antibody 
expression and cancer stage 
(Kruskal–Wallis test)
Association between antibody 
expression and cancer 
recurrence (Mann–Whitney 
test)
CD31 Increased expression in vascu‑
lar cells (p < 0.001)
Not significant (p = 0.257) Significant (p = 0.002) Not significant (p = 0.69)
Thrombomodulin Reduced/loss of expression 
(p < 0.010)
Not significant (p = 0.827) Not significant (p = 0.039) Not significant (p = 0.89)
HER‑2 Increased expression 
(p < 0.032)
Significant (p = 0.003) Significant (p < 0.001) Not significant (p = 0.91)
S100P Increased expression 
(p < 0.001)
Not significant (p = 0.902) Not significant (p = 0.344) Not significant (p = 0.23)
CEACAM‑1 Reduced/loss of expression 
(p < 0.001)
Not significant (p = 0.045) Significant (p = 0.005) Not significant (p = 0.65)
COX‑2 Increased expression 
(p < 0.001)
Not significant (p = 0.619) Not significant (p = 0.439) Not significant (p = 0.98)
VEGFR‑3 Increased expression 
(p < 0.001)
Not significant (p = 0.123) Not significant (p = 0.231) Not significant (p = 0.38)
Page 9 of 11Ella‑Tongwiis et al. BMC Urol          (2020) 20:187  
With regards to cancer stage, our results are in con-
trast with others [5] who reported significant associa-
tions between COX-2 and cancer stage. Although both 
endometrial carcinoma (EC) and BC are of epithelial 
origin, differences in sample size (183 EC vrs 35 BC), 
duration of follow up (5 yrs. for EC vrs 2 yrs. for BC) 
and different antibody clones, may explain the differ-
ences in results reported by both studies.
The relationship between antibody expression (at 
diagnosis) vs BC recurrence was not significant. None-
theless, the expression patterns of COX-2 in BC, 
reported in this present study, should be investigated 
further using larger sample sizes and longer follow up 
periods. COX-2 seems to be epithelial cancer specific 
and may be a useful marker for monitoring and man-
agement of BC patients following TURBT.
Anti-S100P was investigated in this present study 
because its cellular expression may interact with 
growth factors and their receptors, leading to several 
effects such as tumour proliferation [9]. The results 
from this present study showed that S100P was signifi-
cantly expressed in BC cells in comparison with nor-
mal Bladder tissue and suggests this protein may be a 
good marker for identification of BC. In a similar study, 
S100A8 (which belongs to the same family as S100P) 
was highly expressed in TCC tissues compared to nor-
mal cells [38]. In disagreement with that study however, 
there was no correlation between S100P expression and 
patients’ cancer grade and stage in this present study.
Although it can be appreciated that S100P will be 
higher in high grade tumours due to increased cell pro-
liferation [39], that observation was not made in this 
present study and could potentially be due to low sam-
ple size. Furthermore, comparing S100P at diagnosis, 
with S100P at 2–5 years following treatment, may pro-
vide confirmatory information with regards to recur-
rence and long-term outcome measures.
With regards to recurrence however, findings disa-
gree with other researchers [39] who observed that 
positive S100P expression was strongly associated with 
early recurrence in HCC patients. Difference in patient 
cohorts and sample sizes may explain these variations. 
The results from this study nonetheless provides new 
information with regards to S100P staining in blad-
der tumour cells as well as its association with cancer 
grade, stage and recurrence following treatment via 
TURBT.
In various human cancers, different HER-2 rates and 
patterns have been reported [40–42]. HER-2 expres-
sion was therefore investigated in this present study 
due to its links to cancer growth in various human can-
cers, especially its utility in breast cancer treatment and 
management.
Our findings suggest that HER-2 was significantly 
higher in bladder tumour cells, compared to normal 
tissues. As a protein involved in signal transduction 
leading to increased cell proliferation, the increased 
expression observed in this present study potentially 
implicates HER-2 in BC growth. These observations 
complement results by others [43] who reported higher 
HER-2 expression in colorectal cancer cells com-
pared to normal controls and another group [44] who 
also reported higher HER-2 in breast cancer patients. 
The differences between the studies however is that, 
this present study provides detailed information with 
regards to antibody clone, scoring system and opti-
mises IHC protocol to the Ventana IHC autostainer.
High grade (G3) patients presented with higher 
HER-2 expression compared with low grade (G1), in 
agreement with [45], although their observations were 
made in breast cancer patients. These findings none-
theless suggest that HER-2 results in higher rate of cell 
differentiation that potentially leads to increased risk of 
recurrence and metastasis in BC patients.
High stage tumours (pT1/pT2) also presented with 
high HER-2, which complement findings from a previ-
ous study [45] involving breast cancer. It can be appre-
ciated that, increasing HER-2 will lead to increased 
activation of the so-called MAPK pathway, which 
explains the association with aggressive tumour 
behaviour.
There was also a significant increase in VEGFR-3 in 
bladder tumour cells, compared to those in normal tis-
sues. In a previous study [4], VEGF in colonic adeno-
carcinoma showed intensely positive staining compared 
to normal control tissues. However, control tissues 
were moderately positive for VEGF indicating the 
potential likelihood of false positive reporting. In this 
present study, there was also non-specific VEGFR-3 
staining within nuclei of some underlying muscle 
cells, lymphatic endothelial cells and basal tissue cells. 
This observation in this and other study highlights 
the unspecific nature of VEGF staining, and raises the 
issues with standardisation in reporting slides.
A limiting factor for this study is the relatively low 
sample size. Validation of the findings larger multicen-
tre studies could provide clear evidence of a usable bio-
marker profile as an adjuvant to BC management.
Future studies may also investigate antibody tissue 
immunoreaction, serum expression and urine levels 
simultaneously in all patients. This could provide much 
clearer data to enhance the search for a usable bio-
marker profile.
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Conclusion
It is proposed that by allowing urological surgeons 
access to laboratory markers such as HER-2, Throm-
bomodulin, CEACAM-1 and CD31, potentially, in the 
future, these biomarkers may be used in addition to, or 
in combination with, currently used scoring systems to 
predict cancer recurrence and progression.
Ultimately, our research findings may allow cur-
rent NHS post-operative care protocols to be revised, 
improved and implemented within 6–8 years, although 
larger studies are needed in this area of research in 
order to make an impact on a national scale, and to 
promote good practice in the field of urology, pertain-
ing to BC.
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